Myocardial Viability

Definition

Myocardial viability, at the cellular level, refers to cardiomyocytes that are alive, defined by intact cellular, metabolic, and microscopic contractile function. In clinical practice, viability is defined as dysfunctional myocardium at rest with a potential for functional recovery after restoration of normal blood supply. The two principal forms are myocardial hibernation (chronic downregulation of contractile function with reduced resting flow) and myocardial stunning (transient contractile dysfunction caused by reversible hypoperfusion with near-normal resting flow).

Key Concepts

Hibernation vs Stunning

• Myocardial stunning: Transient contractile dysfunction caused by brief ischemic episodes; resting coronary flow is normal or near-normal; coronary flow reserve (CFR) is reduced; repetitive stunning causes cardiomyocyte structural changes (glycogen accumulation, loss of sarcomeres, sarcoplasmic reticulum, and T-tubules). (sources/imaging-viability-aha-2020, rating: very high)
• Myocardial hibernation: Chronic contractile dysfunction with reduced resting blood flow; originally conceived as adaptive, but experimental data suggest reduced resting flow in hibernation may be a consequence of contractile dysfunction (from repetitive stunning) rather than its cause. (sources/imaging-viability-aha-2020, rating: very high)
• Continuum: Stunning → hibernation is a spectrum; structural changes eventually become irreversible, leading to ischemic cardiomyopathy. Whether resting flow is normal or reduced, CFR is decreased in both states, driving repetitive demand ischemia and impaired calcium handling. (sources/imaging-viability-aha-2020, rating: very high)

Significance of Identifying Viable Myocardium

• Dysfunctional but viable myocardium has potential for contractile recovery after revascularization.
• Scar extent (non-viable myocardium) correlates with LV adverse remodeling and increased risk of sudden cardiac death. (sources/imaging-viability-aha-2020, rating: very high)
• Hibernating myocardium creates a substrate for ventricular tachyarrhythmias. (sources/imaging-viability-aha-2020, rating: very high)
• To achieve significant global LVEF improvement (8–10%), approximately 25–30% of myocardial segments must demonstrate viable but dysfunctional tissue. (sources/imaging-viability-aha-2020, rating: very high)

LGE-CMR: Transmural Extent and Functional Recovery

The transmural extent of LGE is the primary CMR tool for viability stratification — each tier carries a stepwise probability of contractile recovery after revascularization:

Kim et al., NEJM 2000. (sources/imaging-viability-aha-2020, rating: very high)

• Wall thinning alone (EDWT <5.5 mm) has 94% sensitivity but only 52% specificity for functional recovery; ~20% of thinned segments without LGE recover contractile function after revascularization (Shah et al., JAMA 2013). (sources/imaging-viability-aha-2020, rating: very high)
• LGE sensitivity for predicting segmental recovery: 95%, NPV 90% (meta-analysis, 24 CMR studies). (sources/imaging-viability-aha-2020, rating: very high)
• Dobutamine CMR specificity for predicting recovery: 91%, PPV 93% — the highest of all modalities. (sources/imaging-viability-aha-2020, rating: very high)

Comparative Performance of Imaging Modalities

All modalities predict a similar degree of global LVEF improvement after revascularization (8–10%), regardless of imaging method used.

Pooled data from 3034 patients in 105 studies (Romero et al. 2012; Schinkel et al. 2007). (sources/imaging-viability-aha-2020, rating: very high)

• LGE-CMR: Best sensitivity + NPV — useful to rule out viability (if LGE >50% transmural, <10% chance of recovery).
• Dobutamine CMR: Best specificity + PPV — useful to confirm viability will recover.
• PET [18F]-FDG: Best sensitivity among nuclear methods; metabolic mismatch pattern (reduced perfusion + preserved FDG uptake) = hibernating viable myocardium.
• Dobutamine echo (DSE): Biphasic response (initial improvement then ischemic deterioration at high dose) is pathognomonic; Sn 76%, Sp 81%.
• Thallium-201: Redistribution on delayed imaging (4–24h) defines viable tissue; highest sensitivity among nuclear agents.

PET [18F]-FDG Viability Protocol

• Resting MPI first: if no perfusion defect, proceed to ischemia evaluation; if perfusion defect present, proceed to metabolic imaging.
• Three patterns: (1) mismatch = hibernating viable myocardium; (2) matched absence = transmural scar; (3) matched reduction = non-transmural scar.
• Patient preparation: 6-hour fast → glucose load (25–50 g oral) ± insulin to promote myocardial glucose uptake.
• Quantitative myocardial blood flow reserve may identify patients who benefit from revascularization independently of viability status. (sources/imaging-viability-aha-2020, rating: very high)

Evidence from Major Clinical Trials

• STICH trial (NEJM 2011/2019; n=1212, LVEF ≤35%): CABG + GDMT reduced 10-year all-cause and CV mortality vs GDMT alone — confirming CABG benefit in ischemic cardiomyopathy. (sources/imaging-viability-aha-2020, sources/CCS-AHA-2023, rating: very high)
• STICH viability substudy (n=618; SPECT or dobutamine echo): Patients with viable myocardium had lower 5-year mortality (33% vs 50%) but viability status did NOT discriminate who benefited from CABG vs GDMT alone — no significant treatment-by-viability interaction for mortality. LVEF improved similarly in GDMT-only and CABG patients with viable myocardium; 10-year survival was not related to whether LVEF increased. (sources/imaging-viability-aha-2020, rating: very high)
• PARR-2 trial (PET-guided management): PET viability imaging did not improve survival vs standard care. Post-hoc analysis suggested benefit only when PET guidance was strictly adhered to. (sources/imaging-viability-aha-2020, rating: very high)
• REVIVED-BCIS2 (n=700, LVEF ≤35%, viable by imaging): PCI + GDMT vs GDMT alone — no difference in all-cause death or HF hospitalisation at median 3.4 years. (sources/CCS-AHA-2023, rating: very high)
• Interpretation: Modern GDMT (particularly beta-blockers) has advanced substantially since earlier observational studies showing viability-guided revascularization benefit. The incremental survival benefit of revascularization over GDMT alone may have diminished to the point where imaging-based viability assessment cannot separate responders from non-responders.

Clinical Decision Algorithms

• Chronic ischemic LV dysfunction: Assess anginal symptoms → if no angina, perform viability imaging → weigh revascularization feasibility, extent of LV remodeling (ESV >130 mL = worse outcomes), and surgical risk alongside imaging. (sources/imaging-viability-aha-2020, rating: very high)
• Subacute ischemic LV dysfunction: Similar framework; 201Tl redistribution or PET-FDG mismatch documents stunned but viable territory, providing justification for revascularization risk. (sources/imaging-viability-aha-2020, rating: very high)
• Note: These algorithms are consensus-based (not clinically validated in the document).

Contradictions / Open Questions

• STICH viability substudy vs prior observational evidence: Retrospective meta-analyses and systematic reviews reported improved survival with revascularization in viable myocardium. The STICH RCT refuted this using the same imaging methods — likely explained by improved contemporary GDMT adherence (beta-blockers) that was absent in earlier studies. The critical unresolved question: would CMR-guided viability (rather than SPECT/echo) have yielded a different result? (sources/imaging-viability-aha-2020, rating: very high)
• Viability predicts contractile recovery but not survival: The STICH substudy demonstrated that improved LVEF after CABG did not translate to improved survival — functional recovery is an insufficient surrogate for patient benefit. Benefits may extend to diastolic relaxation, arrhythmia burden, symptom relief, and QoL, none of which were tested. (sources/imaging-viability-aha-2020, rating: very high)
• Single dichotomized viability test insufficient: No single imaging modality expressed in a binary fashion (viable vs not) captures the physiological continuum of ischemic myocardium; quantitative, multi-modal approaches may be needed but have not been validated in RCTs. (sources/imaging-viability-aha-2020, rating: very high)
• Extensive LV remodeling negates viability benefit: LV end-systolic volume >130 mL predicts 38% higher cardiac events after revascularization despite metabolic viability — the LV remodeling threshold attenuates functional benefit; imaging-guided viability assessment does not account for this modifier. (sources/imaging-viability-aha-2020, rating: very high)

Connections

• Related to concepts/Late-Gadolinium-Enhancement
• Related to entities/Heart-Failure
• Related to entities/Chronic-Coronary-Disease
• Related to entities/DCM
• Related to concepts/HFpEF
• Related to sources/imaging-viability-aha-2020

Sources

• sources/CCS-AHA-2023
• sources/imaging-viability-aha-2020